Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

M. A. Elliott, S. Verstovsek, D. Dingli, S. M. Schwager, R. A. Mesa, C. Y. Li, A. Tefferi

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

We recently developed a modified Dupriez prognostic scoring system (PSS) that effectively discriminated between high-, intermediate-, and low-risk young patients (age ≤60 years) with primary myelofibrosis (PMF) based on the respective presence of none, one, or two or more of the following parameters: hemoglobin <10 g/dL, leukocyte count <4 or >30 × 109 L-1, and platelet count <100 × 109 L-1. The current study (n = 129; median age, 52 years; 69 males) reveals, on multivariable analysis, that an absolute monocyte count of ≥1 × 109 L-1 carries an independent predictive value (p = 0.02), for an inferior survival, in addition to that provided by hemoglobin level (p = 0.002), platelet count (0.02), and leukocyte count (p = 0.16). The inclusion of the monocyte count as a fourth risk factor enabled the construction of a new and improved Mayo PSS; median survival was 173, 61, and 26 months in the absence of all four (low-risk), three (intermediate-risk), or two or less (high-risk) adverse features, respectively (p < 0.0001). The independent prognostic value of monocytosis was validated in a separate database of 97 patients with PMF from another institution.

Original languageEnglish (US)
Pages (from-to)1503-1509
Number of pages7
JournalLeukemia Research
Volume31
Issue number11
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

    Fingerprint

Keywords

  • Monocytosis
  • Myelofibrosis
  • Myeloproliferative disorder
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this